Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Weight gain during a double-blind multidosage clozapine study.

de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM.

J Clin Psychopharmacol. 2007 Feb;27(1):22-7.

PMID:
17224708
2.

Plasma clozapine concentration coefficients of variation in a long-term study.

Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM.

Schizophr Res. 2005 Jan 1;72(2-3):131-5.

PMID:
15560958
3.

Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.

Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E.

Psychopharmacology (Berl). 2000 Jan;148(1):83-9.

PMID:
10663421
4.

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

Lu ML, Lane HY, Lin SK, Chen KP, Chang WH.

J Clin Psychiatry. 2004 Jun;65(6):766-71.

PMID:
15291653
5.

Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking.

Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R, McLean M, Caetano D.

J Clin Psychopharmacol. 2016 Apr;36(2):120-4. doi: 10.1097/JCP.0000000000000476.

PMID:
26872115
6.

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P.

J Clin Psychopharmacol. 2001 Aug;21(4):398-407.

PMID:
11476124
7.

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

Couchman L, Morgan PE, Spencer EP, Flanagan RJ.

Ther Drug Monit. 2010 Aug;32(4):438-47. doi: 10.1097/FTD.0b013e3181dad1fb.

PMID:
20463634
8.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
9.
10.

Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.

Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW.

J Clin Psychiatry. 1999 Jan;60(1):36-40.

PMID:
10074876
11.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
12.

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.

Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr.

Ann Clin Psychiatry. 2003 Sep-Dec;15(3-4):181-6.

PMID:
14971863
13.

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.

Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM.

Biol Psychiatry. 2008 Mar 1;63(5):524-9. Epub 2007 Jul 25.

PMID:
17651705
14.

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC.

Acta Psychiatr Scand. 2007 Feb;115(2):101-5.

PMID:
17244173
15.

Plasma concentrations of high-dose olanzapine in a double-blind crossover study.

Kelly DL, Richardson CM, Yu Y, Conley RR.

Hum Psychopharmacol. 2006 Aug;21(6):393-8.

PMID:
16850522
16.

The significance of sampling time in therapeutic drug monitoring of clozapine.

Jakobsen MI, Larsen JR, Svensson CK, Johansen SS, Linnet K, Nielsen J, Fink-Jensen A.

Acta Psychiatr Scand. 2017 Feb;135(2):159-169. doi: 10.1111/acps.12673. Epub 2016 Dec 6.

PMID:
27922183
17.

Double-blind study of clozapine dose response in chronic schizophrenia.

Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, Odom-White A, Turner RM.

Am J Psychiatry. 1999 Nov;156(11):1744-50.

PMID:
10553738
18.

Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.

Cooper GD, Harrold JA, Halford JC, Goudie AJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):428-36. Epub 2007 Sep 22.

PMID:
17933447
19.

Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram.

Perry PJ, Bever KA, Arndt S, Combs MD.

Biol Psychiatry. 1998 Oct 15;44(8):733-8.

PMID:
9798077
20.

Clozapine: more than 900 mg/day may be needed.

Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer EP, Flanagan RJ.

J Psychopharmacol. 2009 Mar;23(2):206-10. doi: 10.1177/0269881108089819. Epub 2008 May 30.

PMID:
18515467

Supplemental Content

Support Center